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Abstract  
 
Background: 
A Health Technology Assessment was conducted to evaluate the relative clinical and cost- 
effectiveness of minimally invasive techniques (foam sclerotherapy (FS), endovenous laser 
ablation (EVLA) and radiofrequency ablation (RFA)) for managing varicose veins, in 
comparison with traditional surgery. 
 
Methods: 
A systematic review of randomised controlled trials (RCTs) to assess the effectiveness of 
minimally invasive techniques compared with other treatments, principally surgical stripping, 
in terms of recurrence of varicose veins, Venous Clinical Severity Score (VCSS), pain and 
quality of life. Network meta-analysis and exploratory cost-effectiveness modelling were 
performed. 
 
Results: 
The literature search conducted in July 2011 identified 1453 unique citations: 34 RCTs (54 
papers) satisfied the criteria for effectiveness review. Differences between treatments were 
negligible in terms of clinical outcomes, so the treatment with the lowest cost appears to be 
most cost-effective. Total FS costs were estimated to be lowest and it was marginally more 
effective than surgery. However, relative effectiveness was sensitive to the model time 
horizon. Threshold analysis indicated that EVLA and RFA might be considered cost-effective 
if their costs are similar to surgery. These findings are subject to various uncertainties, 
including the risk of bias present in the evidence base and variation in reported costs. 
 
Conclusion: 
This assessment of the currently available evidence suggests there is little to choose between 
surgery and the minimally invasive techniques in terms of efficacy or safety, so the relative 
costs of the treatments becomes one of the deciding factors. High quality RCT evidence is 
needed to verify and further inform these findings. 
 
 
 
 
 
 
Introduction 
The prevalence of varicose veins in the UK has been reported to be between 20-40% in 
adults. The NHS performed over 33,000 surgical procedures in 2010-11 to treat varicose 
veins. However, the perceived low priority of varicose veins in economically straitened times 
may explain the recent reductions in varicose vein activity in England and Wales.1. 
Conventional surgery (ligation and stripping) remains the most frequently performed 
procedure in the National Health Service (NHS)2;3 although there are regional variations in the 
type of procedures performed.2 However, ligation and stripping has been associated with a 
range of adverse effects such as wound infection, haematoma, lymph leaks, pain, scarring, 
nerve injury, Deep Vein Thrombosis (DVT) and long post-operative recovery.4-7 
Conventional non-foam sclerotherapy, is considered faster but less effective than surgical 
VWULSSLQJKHUHDIWHU³VXUJHU\´.8 
 
The clinical signs and symptoms of venous disease may be classified using the CEAP 
classification: Clinical status; Etiology; Anatomy; and Pathophysiology.9-11 This ranges from 
C0 (no signs of venous disease) to C6 (active venous ulcer). C2 indicates varicose veins. The 
degree of severity of pain and other clinical signs or symptoms can be measured according to 
the Venous Clinical Severity Score (VCSS).12;13 The VCSS may be used to gauge clinical 
severity before and after intervention, i.e. to measure the efficacy of an intervention. The 
higher the score, the worse the disease severity. The presence of reflux is identified 
principally by duplex ultrasound (DUS). The criteria usually taken as indicating pathological 
reflux are the presence of venous flow reversal for >0.5 to 1.0 second with proximal 
compression, the Valsalva manoeuvre, or distal compression and release.14 
 
The principal outcomes associated with treatment for varicose veins are symptom relief and 
symptom severity, recurrence of varicosities, as well as the occurrence of new varicosities in 
the same limb, and retreatment. Reported recurrence rates vary widely depending on the 
nature of the surgical technique performed and method of assessment. For conventional 
stripping and ligation surgery, two-year recurrence rates of up to 33% have been reported15;16, 
rising to 41% for 5 years and to up to 70% at over 10 years.17;18 Surgical procedures for 
recurrence can therefore place considerable demand on the health services. Other outcomes of 
interest are health-related quality of life (HRQoL), patient treatment satisfaction, and the 
occurrence of related post-operative complications. 
 
New minimally invasive treatments offer alternative methods of ablating incompetent veins, 
particularly the Greater Saphenous Vein. These treatments typically involve use of laser 
(endovenous laser ablation, EVLA)19, radiofrequency probe (RFA)20 or foam sclerosant 
(FS).21 They are increasingly widely used and might offer potential benefits such as faster 
recovery, reduced complications, fewer physical limitations and increased HRQoL. In terms 
of active intervention, recent Guidance from the National Institute for Health and Care 
Excellence (NICE) recommends the use of EVLA or RFA; if this is considered ´XQVXLWDEOH´, 
then FS should be used, and, if this technique is deemed ´XQVXLWDEOH´, then surgery should be 
used.22 The study reported here was funded as a Health Technology Assessment report by the 
National Institute of Health Research (NIHR); the full detailed report is available elsewhere.23 
It aimed to evaluate the clinical and cost effectiveness of the different minimally invasive 
methods of managing varicose veins compared with conventional surgery. 
 
 
Methods 
 
Clinical effectiveness 
Inclusion and exclusion criteria 
To be included in the review, a study had to be a randomised controlled trial (RCT) of adults 
aged 16 years or more who were being treated specifically for varicose veins and who 
received one of the following interventions (EVLA, RFA or FS). The comparator could be 
any of these treatments, surgery or conservative management. Outcomes included failure of 
the procedure, i.e. the procedure was incomplete; or occlusion or obliteration was not 
achieved or was not sustained for more than one month; technical recurrence (as distinct from 
initial episode), i.e. the presence of reflux, recanalisation or new varicose veins in a treated 
limb, diagnosed by duplex ultrasound scanning (DUS); Venous Clinical Severity Score 
(VCSS); pain; time to return to work or normal activity; and post-operative complications 
(adverse events). Trials comparing different forms of the same intervention were excluded. 
Only the meta-analysed outcomes of technical recurrence, VCSS and pain are reported in this 
article.  
 
Search strategy and study selection 
A systematic review of the literature and (network) meta-analysis was undertaken in 
accordance with the general principles recommended in the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) statement.24 A comprehensive search was 
undertaken to identify systematically clinical effectiveness literature comparing different 
methods for the management of varicose veins.  The search involved combining terms for the 
population (varicose veins) with terms for the interventions of interest, i.e. the minimally 
invasive techniques. The full search strategy is available in the full report.23 All searches were 
performed in July 2011. Eleven electronic databases were searched from inception for 
published and unpublished research evidence: MEDLINE, EMBASE, CINAHL, The 
Cochrane Library, Biological Abstracts, Science and Social Science Citation Indices, 
Conference Proceedings Citation Index- Science (CPCI-S), UK Clinical Trials Research 
Network (UKCRN), Current Controlled Trials and Clinical Trials.gov. All citations were 
imported into reference management software and titles and abstracts of all unique citations 
were screened independently by two reviewers using the inclusion criteria outlined below. 
Disagreements or queries were resolved by consensus or with reference to a third team 
member where necessary. The full papers of all potentially relevant citations were assessed 
for inclusion and reference-tracking of all included studies and relevant reviews was 
performed to identify additional, relevant studies not retrieved by the search of electronic 
databases. 
 
Data extraction, critical appraisal and synthesis 
Data extraction was performed by one reviewer into a standardised form and independently 
checked for accuracy by a second reviewer. Discrepancies were resolved by discussion. 
Critical appraisal of included trials was performed by one reviewer, using appropriate criteria 
adapted from a published checklist for surgical interventions, and independently checked for 
accuracy by a second. Discrepancies were resolved by discussion between reviewers. 
Blinding of patients and outcome assessors were not retained as criteria because the 
techniques generally did not permit such blinding, so the risk of detection bias was inherently 
high in all studies. 
 Methods of data synthesis 
Technical recurrence, VCSS and pain score data were tabulated and, where data were 
appropriate, included studies were combined in a random-effects network meta-analysis, 
which allows for heterogeneity in treatment effects across studies. Randomisation and 
analysis in the primary studies was described as being by patient or by limb when patients 
were unilateral; when patients were bilateral, randomisation was by limb. Data were therefore 
all per limb or per patient; no data were per procedure (i.e. there were no data where multiple 
procedures were conducted on the same limb). The analysis was conducted using Markov 
chain Monte Carlo (MCMC) simulation implemented in the WinBUGS and OpenBugs 
software packages.25;26 The principal analysis compared the hazard of having technical 
recurrence when treating with EVLA, RFA and FS, relative to the common comparator of 
surgery using a complimentary log-log link function assuming that the underlying survivor 
functions follow Weibull distributions with separate shape and scale parameters to allow for 
the possibility of non-proportional hazards; a summary of the treatment effects is presented 
for 6 months, 1 year and 2 years. For VCSS and pain scores, the statistical model assumed a 
normal distribution for the observed sample means. Convergence of the models to their 
posterior distributions was assessed using the Brooks-Gelman-Rubin convergence statistic.27 
Convergence occurred after 200,000 iterations for technical recurrence, after 10,000 iterations 
for VCSS and after 30,000 iterations for pain.  Full details of the analysis are given 
elsewhere.23 
 
Cost-effectiveness 
 
Model Overview 
The model was developed as a discrete event simulation (DES) model in Simul8® to simulate 
the experience of patients undergoing treatment for varicose veins. A DES model was chosen 
to allow non-constant hazard in the time to treatment failure/technical recurrence. This 
method also obviates the need for arbitrary time cycles. The baseline model had a perspective 
of ten years, chosen as a reasonable time over which to extrapolate the time to failure data. 
Costs were reported in 2011-12 British Pound Sterling; quality adjusted life years (QALYs) 
were used as the measure of effectiveness. The analysis took the perspective of the UK NHS 
and personal social services. All costs and benefits are discounted at a rate of 3.5%, as 
recommended NICE.28 Both probabilistic (PSA) and deterministic sensitivity analysis were 
undertaken. 
 
The model structure 
The model structure is illustrated in Figure 1. Ovals represent events (numbered 1 to 3) and 
oblongs health states (A to D). Treatments included in the model are surgery, FS, EVLA, and 
RFA (Event 1). Costs and a loss of utility from the short term adverse effects of treatment are 
assigned according to the treatment. Treatment may result in technical immediate 
(anatomical) success (states A and B) or failure (states C and D). If a failure, it is assumed 
that all patients will have further treatment with foam until technical success is achieved 
(Event 2). Patients with a successful clinical outcome nevertheless still have a probability of 
remaining symptomatic (state B). Thus initial treatment may result in one of two health states 
(A,B) based on the presence or absence of symptoms. Outcomes of varicose vein procedures 
are complex. Several disease-specific quality of life measures have been developed for 
varicose veins in recognition of the fact that whilst symptom relief is associated with clinical 
or anatomical outcomes, these are poor predictors of operatLYH VXFFHVV IURP WKH SDWLHQW¶V
perspective.29;30 For example, in a study of FS no correlation was found between changes in 
the Aberdeen Varicose Veins Questionnaire (AVVQ), a patient-reported measure of outcomes 
and quality-of-life, and venous refill times.29 Also, Merchant reports a high proportion of 
patients experiencing symptom improvement despite anatomical failure following RFA (70%-
80%, compared to 85%-94% in limbs with anatomical success).30 In the model it was 
therefore not assumed that technical failure equates to the patient being symptomatic. Instead 
patients with technically successful and technically failed procedures have differing 
probabilities of being asymptomatic, with differing utility values attached to symptomatic and 
asymptomatic states. Patients may die at any time of all-cause mortality.  
 
Adverse events, other than post-operative pain, are not included in the model because most 
adverse events of treatment, such as infection, haematoma, paraesthesia and phlebitis are 
relatively mild, of short duration and require no treatment. An exception is DVT, which can 
occasionally lead to death. However, the effectiveness review showed that DVT following 
treatment for varicose veins is very rare and so any possible effects on the model results were 
estimated to be negligible. 
 
Figure 1 here: Model structure 
  
Model Parameters  
Uncertainty about parameters representing disease recurrence data and post-operative pain 
were sourced from the network meta-analysis (see Results). The proportion of patients 
requiring treatment for initial failure (treatment failure by one month) was determined from 
the time to failure distribution and top-up treatments for residual side branches and accessory 
saphenous veins estimated from additional meta-analysis of data from studies included in the 
effectiveness review. Both were assumed to be treated with FS.Studies varied in their use of 
phlebectomy concomitant with the primary procedure. In the model the initial procedure 
includes a proportion that would be undergoing concomitant phlebectomy in keeping with the 
trial evidence. Most used FS rather than phlebectomy for residual varicosities requiring 
secondary procedures unless there was recurrent incompetence. It was therefore assumed that 
60% of late (after one month) retreatments were surgical procedures (stripping) and 40% FS. 
The proportion of patients asymptomatic following a technically failed or successful 
procedure was taken from the literature.30;31 Procedure costs were derived from UK studies 
identified in a systematic search for economic studies of included treatments. However, only 
the cost of surgery was available from more than one study and was quite variable, ranging 
from £660 to £1,420 at 2011/12 prices.32-34 The cost for surgery was therefore taken from 
National Reference costs, but these do not differentiate between the other treatment 
methods.35 The cost of other treatments relative to surgery was published only in a small 
number of studies, so this information had to be used to calculate their cost, as shown Figure 
2. The costs of EVLA were estimated from those for RFA, based on additional equipment 
costs. To address variation in treatment costs a threshold analysis was performed to determine 
the cost at which the minimally invasive treatments might be considered cost-effective. 
Resource use (GP and outpatient visits, duplex scan) associated with retreatment were 
estimated and costed using standard sources.35;36 
To derive an estimate of the utility associated with symptomatic varicose veins a meta-
analysis was undertaken of all studies reporting baseline (pre-treatment) EQ-5D in this 
population.34;37-41 Six relevant studies were identified with 1177 unique patients. Age-
independent estimates were calculated by dividing the reported values by the population 
average utility for the mean study population ages.42 This gave a utility value of 0.88 (se 
0.009) for patients with symptomatic varicose veins. Asymptomatic patients are assumed to 
have the same utility as the general population of their age, so the state utility value is one. In 
the model age-specific utility is calculated by multiplying the state utility by the age-
dependent utility. Loss of utility associated with post-operative pain was estimated from a 
single study reporting both.43 The reduction in EQ-5D utility for each absolute 1% increase in 
VAS pain score was 0.0026. All parameter values are reported in Supplementary Data Table 
S1 except time to recurrence (see Figure 8 in Results section). 
 
Figure 2 here: Initial procedure costs estimated relative to surgery costs 
 
Results 
 
Clinical effectiveness review 
Included studies 
The searches identified 1453 unique citations. See the PRISMA flowchart below (Figure 3). 
Eleven citations represented relevant ongoing trials and 51 citations, representing 31 different 
studies 32;41;43-71, provided data used in the network meta-analyses. Study characteristics for 
these trials are shown in Table S2 (supplementary information). Fourteen trials evaluated 
EVLA against surgery, RFA or FS; thirteen trials compared RFA with surgery, EVLA, FS or 
other comparators; and thirteen trials evaluated FS, principally comparing it with 
conventional surgery. One trial had arms comparing all three minimally invasive techniques.56 
No trial included conservative management as a comparator. The principal, common 
comparator was surgery, i.e. ligation and stripping.  
 
3873 participants were reported as randomised across all trials. The number of randomised 
participants in a single trial ranged from 2845 to 710.48 The mean age of participants ranged 
from 33to 54 years.52;53;72 There was a majority of female participants in every trial; the 
percentage of female participants ranged from 54%52 to 95%.54 In all trials participants were 
required to have varicose veins diagnosed by duplex scanning and categorised according to 
the CEAP score. The vast majority of participants in any trial were C2 on the CEAP score 
(varicose veins), except for three trials, where the majority were C353, C449 or C5.55  The UK 
was the single most frequent location (12 trials); the remainder were conducted in centres 
across thirteen other different countries. 
 
 
Quality of included studies 
The methodological quality assessment of each included study is summarised in Table S3 
(supplementary information). The majority of the trials used in the network meta-analyses 
(e.g. those reporting technical recurrence data for EVLA versus surgery or EVLA versus RFA 
etc.) were at risk of either selection or attrition bias due to inadequate randomisation, 
allocation concealment or intention-to-treat analysis. Only four of the included trials actually 
reported that surgeons were sufficiently experienced across arms in the various procedures, 
thus reducing the likelihood of bias resulting from performance of the various 
techniques.61;63;65;73  
 
Recurrence 
The principal outcome reported by trials was technical recurrence, as defined above. Data 
were available from 23 trials at various follow-up times.41;43-49;51-56;61;72-77 The results 
suggested that there was mild heterogeneity between studies in the shape parameter (0.17; 
95% CrI: 0.01, 0.45) but that there was mild to moderate heterogeneity between studies in the 
scale parameter (0.26; 95% CrI: 0.02, 0.91).  EVLA exhibited the lowest rates of technical 
recurrence relative to surgery, although there was some evidence that this benefit decreases 
over time (2 Year HR, 0.84; 95% CrI: 0.44, 1.81) (see Figure 4). RFA was associated with a 
small and relatively constant lower rate of technical recurrence over time compared with 
surgery (2 Year HR, 0.94; 95% CrI: 0.42, 2.51).  FS was worse than surgery over the first 
year, although there was a small benefit after two years (2 Year HR, 0.92; 95% CrI: 0.43, 
1.60).  In each case there was considerable uncertainty about which intervention was the most 
beneficial. 
 
Figure 4 here: Technical recurrence 
 
Venous Clinical Severity Score (VCSS) 
Thirteen studies met the inclusion/exclusion criteria for VCSS as an outcome, although 1 year 
data was available from only 6 studies.43;46;57;63;66;78  The between study standard deviation 
(SD) was estimated to be 0.22, which is indicative of mild to moderate heterogeneity in 
treatment effect between studies (95% CrI: 0.01, 1.79). The VCSS for both FS and EVLA 
were lower than for surgery, i.e. patients and clinicians reported fewer clinical symptoms for 
these treatments compared to surgery. (See Figure 5). 
 
Figure 5 here: VCSS 
 
Pain score 
Eleven trials reported measuring pain using a form of visual analogue scale (1-10 or 1-100) 
for a period between three and 14 days post-operation and were included in the network meta-
analysis.41;45;53;56-59;61;63;64;79 The between study standard deviation was estimated to be 0.48; 
(95% CrI: 0.06, 1.12), which is indicative of mild to moderate heterogeneity in treatment 
effect between studies. The interventions that exhibited the lowest pain scores compared to 
surgery were RFA (mean difference, -1.26 95% CrI: -1.95, -0.61) and FS (mean difference, -
0.80 95% CrI: -1.93, 0.30). (See Figure 6) 
 
Figure 6 here: Pain scores 
 
 
Adverse events 
In general, serious adverse events, such as DVT or pulmonary embolism (PE) were rare. 
Eleven studies reported on these outcomes but only five studies reported that any such 
complication actually occurred.46;48;56;63;80  The three trials reporting the highest numbers of 
these adverse events, i.e. Wright78, Rasmussen et al., 201187 and Shadid et al.,125, also had the 
largest sample sizes of all included studies in the review48;56;80, with Wright et al48 reporting a 
substantially higher rate than any other study. However, this disproportionate rate can be 
H[SODLQHGE\WKHLQWHUYHQWLRQ7KH³VARISOLVE®´WHFKQLTXH(BTG, London, UK) applied 
in this trial was new and the amount of foam used was altered part way through the trial 
because of the high DVT rate: the initial amount of foam (60mL) was reduced to 30mL. No 
DVT was reported for the 95 participants who subsequently received this lower dose. 
 
Summary of effectiveness 
The analysis of the technical recurrence data suggested that the benefit of treatment with 
EVLA and FS varied over time. In particular, the early benefit associated with EVLA relative 
to surgery was less at 2 years than at 6 months. However, the results were inconclusive in 
determining which intervention was the most effective. The analysis of the VCSS data 
suggested that FS was the most effective intervention. The analysis of the pain score data 
suggested that RFA was the most effective treatment. 
 
 
Cost-effectiveness 
 The results of the PSA analysis, with costs and QALYs discounted at a rate of 3.5%, are 
shown in Figure 7. Although there is an element of retreatment, the total costs of treatment 
are primarily comprised of the initial treatment cost, with RFA the most expensive procedure 
and FS the least costly option.  All of the minimally invasive treatments result in more 
QALYs compared to surgery at 10 years, but the QALY differences between surgery, EVLA 
and RFA are negligible: equivalent to less than a day in full health for EVLA compared to 
surgery. 
Figure 7 here: Results of the discounted PSA economic analysis 
 
Foam is less costly than surgery and marginally more effective, and can thus be said to 
dominate surgery. The probability of it being the most cost-effective treatment is above 90% 
for willingness to pay thresholds in the range £20,000 to £50,000. The Incremental Cost 
Effectiveness Ratios (ICERs) for EVLA and RFA, in comparison to surgical stripping, show 
they are not cost-effective at usually accepted levels.28   
The full results of the univariate sensitivity analysis are reported elsewhere.23 The results were 
not sensitive to uncertainty associated with most parameters, with the exception of the 
disutility associated with post-operative treatment, and the model time horizon. The results for 
FS compared to surgery were potentially sensitive to disutility associated with treatment, a 
parameter derived from the network meta-analysis of reported pain at approximately 10 days 
(see Figure 6). By 10 days post-operative pain has already subsided, and therefore the 
analysis may not fully reflect differences between the treatments. Also the relationship 
between post-operative pain and utility was based on limited data.43  
 
The model time horizon has the potential to affect results due to differences between the 
treatments in post-operative pain and recurrence rates. (See Figures 4 and 8) For EVLA and 
RFA the incremental QALYs are greater and the costs lower with increasing timespan as their 
failure rates are lower than for surgery (Hazard ratio [HR] at one year 0.77 for EVLA, 0.93 
for RFA), so the ICERs are lower the longer the model time horizon, but even run for a 
lifetime the ICERs do not approach £30,000. RFA results in less post-operative pain than 
EVLA, so RFA results in more QALYs at two years compared to EVLA, but by 10 years 
EVLA has overtaken RFA due to lower failure rates. For FS the picture is more complex. The 
pain associated with treatment is lower than for surgery, resulting initially in higher QALYs. 
However the rate of failure is slightly higher in the first few years compared to surgery (HR 
foam 1.02 at one year) potentially resulting in fewer QALYs for intermediate model 
timespans. In the long term (between 10 years and life) foam has a lower failure rate than 
surgery and leads to a small QALY gain. 
 
Figure 8 here: Probability of technical recurrence by intervention (mean) 
 
 
Summary of cost-effectiveness 
Differences between treatments are negligible in terms of clinical outcomes, so the treatment 
with the lowest cost appears to be most cost-effective. Our central estimate is that total FS 
costs are the lowest and it is marginally more effective than surgical stripping (+0.0015 
QALYs), with a probability of being the most cost-effective treatment above 90% for 
willingness-to-pay thresholds in the range £20,000±50,000. This result is, however, sensitive 
to the model time horizon (i.e. cost-effectiveness is reduced in the shorter term because of the 
early failure rates for this technique). EVLA and RFA both cost more than surgery, and with 
very little difference in QALYs they cannot be considered cost-effective at the usual threshold 
of £20,000±30,000, a result that is robust to parameter variation and model time horizon. 
There is considerable uncertainty in the cost differences between treatments arising from 
different reported costs of the procedures, and in fact these are likely to vary with setting, and 
may also vary over time. Threshold analysis showed that the additional costs of EVLA and 
RFA would have to be not more than £50 and £24 more than surgery, respectively, to be 
considered cost-effective at a threshold of £20,000.23 
 
 
Discussion 
 
This assessment of the evidence published up to August 2011 suggests there is little to choose 
between the minimally invasive techniques in terms of efficacy or cost, and each offers a 
viable, clinically effective alternative to stripping. FS might offer the most cost-effective 
alternative to stripping, within certain time parameters, although there is some uncertainty 
over the longer-term benefits.81 EVLA and RFA both cost more than surgery, and with very 
little difference in QALYs they cannot be considered cost-effective at the usual threshold of 
£20,000 - £30,000.28 However, there was limited cost data for the procedures apart from 
surgery, where reported costs were quite variable. Cost differences between treatments are 
therefore highly uncertain. EVLA and RFA were marginally more effective than surgery so if 
their costs were similar to surgery they would be considered cost-effective. In view of the 
small absolute differences in costs and outcomes between the techniques, other issues of 
importance to patients, such as the less invasive nature of some options, the opportunity to 
avoid larger scars and general anaesthesia may be important in the choice of procedure. 
Furthermore, if wider social benefits, such as speed of recovery and return to work, were to be 
considered in costs, then the minimally invasive techniques might demonstrate further 
benefits over surgery, the majority of studies evaluating  time to return to work or normal 
activity report a significant reduction for the minimally invasive techniques compared to 
surgical stripping.23 
 
All of the effectiveness analyses presented here used only technical rather than symptomatic 
recurrence data, so the true proportion of treated individuals who are likely to present with 
symptoms of recurrence requiring retreatment is not certain. The rates of technical recurrence 
reported here are therefore higher than those encountered in clinical practice because non-
symptomatic patients would not present, even if they were experiencing technical recurrence. 
The findings on initial failure and retreatment, symptomatic recurrence and retreatment for 
recurrence, given in the full report23, are affected by a high degree of uncertainty due to the 
relative infrequency with which such data were reported, as well as the limitations of the 
SULPDU\ VWXGLHV¶ UHSRUWLQJRI WKHVHGDWD Based on projections from trial data the long-term 
risk of a technical recurrence is less for all the minimally invasive treatments compared with 
surgery, although the time to treatment failure curves are quite similar.  
 
The cost-effectiveness model shows that any differences in benefits (QALYs) between the 
different procedures are negligible, but marginally favour the minimally invasive treatments 
relative to surgery. Disutility associated with post-operative pain, although not severe and 
limited to a few days duration, affects the results in the short term (two years), demonstrating 
the limited effects of time to failure on differential QALYs. There are differences in treatment 
costs however and, with little differences in QALYs, incremental net benefits are primarily 
driven by costs. The model results are consistent with other studies in finding that QALY 
differences between treatments are very small.82;83 That of Gohel is also a modelling study 
comparing different treatments for varicose veins.82 However, in other respects the results of 
this model are different. Gohel estimated the costs of treatments from basic units of resource 
(day case, outpatient, equipment costs) and reports day case surgery to be more costly than 
any of the minimally invasive treatments, contrary to more recently published cost studies 
showing the costs of EVLA and RFA to be greater than those for surgery.32;33 Gohel also finds 
surgery to be more effective than the minimally invasive treatments, on the basis of much 
more limited effectiveness data than used in the current analysis.  
 
The new treatments have additional implications for training and the availability of 
equipment. It is possible that there are learning curve effects because the technology is 
continuing to develop and there are various options for some aspects of the treatment, such as 
timing and dosage of energy exposure, which are continuing to be investigated. Some of the 
earlier studies used devices or techniques that have already been superseded and it is possible 
that greater experience and more widespread adoption will result in improved outcomes and 
reduced complications. However, there may also be issues of the availability of the necessary 
skills and equipment, with the resource implications of providing training in the new methods. 
 
The overall results of this research differ from the findings of other published systematic 
reviews and meta-analyses84-89 in their conclusion that FS, EVLA and RFA offer potentially 
equally effective alternatives to surgery and, in the case of FS, a cost-effective alternative 
also. This difference can be explained by the inclusion of more RCT evidence in the present 
report (approximately three times as many relevant RCTs than any previous review, despite 
broader criteria in the majority of the previous reviews), the exclusion of non-RCT and non-
comparative evidence, and the analysis methods used. The recently published clinical practice 
guidelines from both NICE22 and the Society for Vascular Surgery and American Venous 
Forum90 also recommend EVLA, RFA and FS as effective alternatives to surgery and other 
modalities, but the latter only cites a small number of RCTs with short-term follow-up, and 
one or two of the reviews cited here. Also, recent NICE guidance recommends EVLA and 
RFA, if suitable, as initial treatment, before using FS or surgery, although this report has 
found that FS is potentially the most cost-effective treatment over longer time horizons. None 
of the previously published reviews or analyses acknowledged the limitation presented by the 
use of technical recurrence evidence, rather than symptomatic technical recurrence as an 
outcome. 
 
Other than the limitations of the technical recurrence data, the principal uncertainties affecting 
the analyses are in the cost differentials between treatments, which are likely to vary with 
setting, and may vary over time. There was very limited data on the costs of the different 
procedures, but threshold analysis showed that the additional costs of EVLA and RFA would 
have to be not more than £50 and £24 more than surgery, respectively, to be considered cost-
effective at a threshold of £20,000. The differences in clinical effectiveness (time to 
recurrence, post-operative pain) were small. The vast majority of the trials were conducted in 
Western Europe in populations who would typically present in the UK with varicose veins 
and be treated with one of the modalities assessed, so the external validity of the evidence is 
relatively strong for the NHS.  
 
This assessment of the evidence suggests there is little to choose between the minimally 
invasive techniques in terms of technical recurrence, VCSS, pain and adverse events, and 
each offers a viable, clinically effective alternative to surgical stripping. Foam sclerotherapy 
might offer the most cost-effective alternative to surgery, within certain time parameters. 
Training and experience in the minimally invasive techniques might be required before 
relative benefits are apparent. Future trials should aim to measure and report outcomes in a 
standardised manner, which would permit more efficient pooling of their results, e.g. mean 
and Standard Deviation (SD) of all validated and commonly-used measures, such as VCSS 
and EQ-5D. Trial authors should also report both technical and symptomatic recurrence, to 
permit assessment of likely retreatment rates and costs, and utilise surgeons with adequate 
experience of the minimally invasive techniques, if the comparison with surgery (currently 
the most common procedure performed by all surgeons) is to be internally valid. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Model structure 
 
 
 
 
 
Figure 2: Initial procedure costs estimated relative to surgery costs (31;32;34)  
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Disease recurrence 
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Initial procedure 
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Source 
Surgery - £1,155 National reference costs 
Foam sclerotherapy 0.55 £634 Bountouroglou 2006 
RFA 2.28 £2,635 Subramonia 2010 
EVLA 2.02 £2,338 See text 
Figure 3:      PRISMA flowchart
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Figure 4: Technical recurrence: Posterior distribution for the hazard ratios relative to surgery 
at 6 months, 1 year and 2 years  
 
 6 Months 
Median 
(95% CrI) 
[Probability HR >1] 
1 Year 
Median 
(95% CrI) 
[Probability HR >1] 
2 years 
Median 
(95% CrI) 
[Probability HR >1] 
EVLA vs. surgery 0.70 
(0.27, 1.45) 
[0.150] 
0.77 
(0.37, 1.54) 
[0.182] 
0.84 
(0.44, 1.81) 
[0.257] 
RFA vs. surgery 0.92 
(0.39, 2.11) 
[0.409] 
0.93 
(0.42, 2.22) 
[0.411] 
0.94 
(0.42, 2.51) 
[0.421] 
FS vs. surgery 1.12 
(0.53, 2.27) 
[0.659] 
1.02 
(0.49, 1.84) 
[0.524] 
0.92 
(0.43, 1.60) 
[0.359] 
Technical recurrence: the presence of reflux, recanalisation or new varicose veins in a treated limb, diagnosed by duplex 
ultrasound scanning (DUS); CrI: Credible interval; HR: Hazard ratio; EVLA: Endovenous laser ablation; RFA: 
Radiofrequency ablation; FS: Foam sclerotherapy 
 
Figure 5: VCSS: Posterior distribution for the mean difference compared to surgery 
 Median 
(95% CrI) 
Probability of mean difference >0 
EVLA vs. surgery -0.10 
(-0.94, 0.73) 
0.324 
RFA vs. surgery 0.15 
(-0.50, 0.95) 
0.739 
FS vs. surgery -1.63 
(-2.90, -0.42) 
0.015 
CrI: Credible interval; EVLA: Endovenous laser ablation; RFA: Radiofrequency ablation; FS: Foam sclerotherapy 
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Figure 6: Pain scores: Posterior distribution for the mean difference compared to surgery 
 Median 
(95% CrI) 
Probability of mean difference >0 
EVLA vs. surgery 0.10 
(-0.49, 0.64) 
0.653 
RFA vs. surgery -1.26 
(-1.95, -0.61) 
0.001 
FS vs. surgery -0.80 
(-1.93, 0.30) 
0.062 
 CrI: Credible interval; EVLA: Endovenous laser ablation; RFA: Radiofrequency ablation; FS: Foam sclerotherapy 
 
 
Figure 7: Results of the discounted Probabilistic Sensitivity Analysis. An economic analysis of 
treatments for varicose veins 
 
ICER: Incremental cost effectiveness ratio 
 
 
 
 
 
 
 
 
 
Procedure Costs  QALYS Costs  QALYS 
Surgery £1,334 8.0347 - - - 
Foam £804 8.0362 -£530 0.0015 NA 
EVLA £2,637 8.0372 £1,302 0.0025 £518,462 
RFA £2,952 8.0359 £1,617 0.0012 £1,352,992 
ICER Discounted Incremental 
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Figure 8: Probability of technical recurrence by intervention (mean) 
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